January 25, 2016
Gadolinium chelate contrast is not needed when using 18F-FDG PET/MRI to diagnose most solid pediatric malignancies, with the possible exception of focal liver lesions, according to a study published in the Journal of Nuclear Medicine.
Researchers from Stanford University in California sought to evaluate whether administration of gadolinium chelates was necessary for evaluation of pediatric tumors. A total of 119 children were included in the study, 66 boys and 53 girls, with a mean age of 8.1. All underwent contrast-enhanced MRI between 2005 and 2013; 103 patients had primary tumors. The remaining children had lymph node, bone, and/or liver metastases. All were followed for a minimum of one year.